Type 2 diabetes mellitus interacts with obesity and common variations in PLTP to affect plasma phospholipid transfer protein activity

Journal of Internal Medicine

Volumn 271, Issue 5, 2012, Pages 490-498

  Dullaart, R P F ^a   Vergeer, M ^b   de Vries, R ^a   Kappelle, P J W H ^a   Dallinga Thie, G M ^b  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^b ACADEMIC MEDICAL CENTER   (Netherlands)

Author keywords

Obesity; Phospholipid transfer protein; Phospholipid transfer protein gene; Type 2 diabetes mellitus; Waist circumference

Indexed keywords

PHOSPHOLIPID TRANSFER PROTEIN;

ADULT; ARTICLE; CONTROLLED STUDY; DIABETIC PATIENT; FEMALE; GENE; GENETIC POLYMORPHISM; GENETIC VARIABILITY; GENOTYPE ENVIRONMENT INTERACTION; HUMAN; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; PLTP GENE; PREVALENCE; PRIORITY JOURNAL; PROTEIN DETERMINATION; SWEDEN; WAIST CIRCUMFERENCE;

AGED; BIOLOGICAL MARKERS; CARDIOVASCULAR DISEASES; CHOLESTEROL, HDL; DIABETES MELLITUS, TYPE 2; FEMALE; GENE-ENVIRONMENT INTERACTION; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; LIPID METABOLISM; MALE; MIDDLE AGED; NETHERLANDS; OBESITY; PHOSPHOLIPID TRANSFER PROTEINS; POLYMORPHISM, GENETIC; PREVALENCE; RISK FACTORS; TRANSCRIPTION, GENETIC; TRIGLYCERIDES; WAIST CIRCUMFERENCE;

EID: 84860249200     PISSN: 09546820     EISSN: 13652796     Source Type: Journal    
DOI: 10.1111/j.1365-2796.2011.02465.x     Document Type: Article

References (44)

1. van Tol A. Phospholipid transfer protein. Curr Opin Lipidol 2002; 13: 135-9.
2. Vergeer M, Dallinga-Thie GM, Dullaart RPF, van Tol A. Evaluation of phospholipid transfer protein as a therapeutic target. Fut Lipidol 2008; 3: 327-35.
3. Tzotzas T, Desrumaux C, Lagrost L. Plasma phospholipid transfer protein (PLTP): review of an emerging cardiometabolic risk factor. Obes Rev 2009; 10: 403-11.
4. Borggreve SE, de Vries R, Dullaart RPF. Alterations in high-density lipoprotein metabolism and reverse cholesterol transport in insulin resistance and type 2 diabetes mellitus: role of lipolytic enzymes, lecithin:cholesterol acyltransferase and lipid transfer proteins. Eur J Clin Invest 2003; 33: 1051-69.
5. Jiang XC, Qin S, Qiao C et al. Apolipoprotein B secretion and atherosclerosis are decreased in mice with phospholipid-transfer protein deficiency. Nat Med 2001; 7: 847-52.
6. Lie J, de Crom R, van Gent T et al. Elevation of plasma phospholipid transfer protein in transgenic mice increases VLDL secretion. J Lipid Res 2002; 43: 1875-80.
7. Schneider M, Vergès B, Klein A et al. Alterations in plasma vitamin E distribution in type 2 diabetic patients with elevated plasma phospholipid transfer protein activity. Diabetes 2004; 53: 2633-9.
8. Cheung MC, Vaisar T, Han X, Heinecke JW, Albers JJ. Phospholipid transfer protein in human plasma associates with proteins linked to immunity and inflammation. Biochemistry 2010; 49: 7314-22.
9. Schlitt A, Bickel C, Thumma P et al. High plasma phospholipid transfer protein levels as a risk factor for coronary artery disease. Arterioscler Thromb Vasc Biol 2003; 23: 1857-62.
10. de Vries R, Dallinga-Thie GM, Smit AJ, Wolffenbuttel BHR, van Tol A, Dullaart RPF. Elevated plasma phospholipid transfer protein activity is a determinant of carotid intima-media thickness in type 2 diabetes mellitus. Diabetologia 2006; 49: 398-404.
11. Schgoer W, Mueller T, Jauhiainen M et al. Low phospholipid transfer protein (PLTP) is a risk factor for peripheral atherosclerosis. Atherosclerosis 2008; 196: 219-26.
12. Schlitt A, Blankenberg S, Bickel C et al. PLTP activity is a risk factor for subsequent cardiovascular events in CAD patients under statin therapy: the AtheroGene study. J Lipid Res 2009; 50: 723-9.
13. Engler MB, Pullinger CR, Malloy MJ et al. Genetic variation in phospholipid transfer protein modulates lipoprotein profiles in hyperalphalipoproteinemia. Metabolism 2008; 57: 1719-24.
14. Bossé Y, Bouchard L, Després JP, Bouchard C, Pérusse L, Vohl MC. Haplotypes in the phospholipid transfer protein gene are associated with obesity-related phenotypes: the Québec Family Study. Int J Obes (Lond) 2005; 29: 1338-45.
15. Jarvik GP, Rajagopalan R, Rosenthal EA et al. Genetic and nongenetic sources of variation in phospholipid transfer protein activity. J Lipid Res 2010; 51: 983-90.
16. Vergeer M, Boekholdt SM, Sandhu MS et al. Genetic variation at the phospholipid transfer protein locus affects its activity and high-density lipoprotein size and is a novel marker of cardiovascular disease susceptibility. Circulation 2010; 122: 470-7.
17. Riemens S, van Tol A, Sluiter W, Dullaart RPF. Elevated plasma cholesteryl ester transfer in NIDDM: relationships with apolipoprotein B-containing lipoproteins and phospholipid transfer protein. Atherosclerosis 1998; 140: 71-9.
18. Riemens SC, van Tol A, Sluiter WJ, Dullaart RPF. Plasma phospholipid transfer protein activity is lowered by 24-h insulin and acipimox administration: blunted response to insulin in type 2 diabetic patients. Diabetes 1999; 48: 1631-7.
19. Riemens SC, van Tol A, Sluiter WJ, Dullaart RPF. Plasma phospholipid transfer protein activity is related to insulin resistance: impaired acute lowering by insulin in obese Type II diabetic patients. Diabetologia 1998; 41: 929-34.
20. Kaser S, Sandhofer A, Föger B et al. Influence of obesity and insulin sensitivity on phospholipid transfer protein activity. Diabetologia 2001; 44: 1111-7.
21. Dullaart RPF, de Vries R, Dallinga-Thie GM, van Tol A, Sluiter WJ. Plasma cholesteryl ester transfer protein mass and phospholipid transfer protein activity are associated with leptin in type 2 diabetes mellitus. Biochim Biophys Acta 2007; 1771: 113-8.
22. Dullaart RPF, de Vries R, Dallinga-Thie GM, Sluiter WJ, van Tol A. Phospholipid transfer protein activity is determined by type 2 diabetes mellitus and metabolic syndrome, and is positively associated with serum transaminases. Clin Endocrinol (Oxf) 2008; 68: 375-81.
23. Riemens SC, Van Tol A, Sluiter WJ, Dullaart RPF. Acute and chronic effects of a 24-hour intravenous triglyceride emulsion challenge on plasma lecithin: cholesterol acyltransferase, phospholipid transfer protein, and cholesteryl ester transfer protein activities. J Lipid Res 1999; 40: 1459-66.
24. Murdoch SJ, Kahn SE, Albers JJ, Brunzell JD, Purnell JQ. PLTP activity decreases with weight loss: changes in PLTP are associated with changes in subcutaneous fat and FFA but not IAF or insulin sensitivity. J Lipid Res 2003; 44: 1705-12.
25. Laimer MW, Engl J, Tschoner A et al. Effects of weight loss on lipid transfer proteins in morbidly obese women. Lipids 2009; 44: 1125-30.
26. Tzotzas T, Dumont L, Triantos A et al. Early decreases in plasma lipid transfer proteins during weight reduction. Obesity (Silver Spring) 2006; 14: 1038-45.
27. Oomen PH, van Tol A, Hattori H, Smit AJ, Scheek LM, Dullaart RPF. Human plasma phospholipid transfer protein activity is decreased by acute hyperglycaemia: studies without and with hyperinsulinaemia in Type 1 diabetes mellitus. Diabet Med 2005; 22: 768-74.
28. Tu AY, Albers JJ. Glucose regulates the transcription of human genes relevant to HDL metabolism: responsive elements for peroxisome proliferator-activated receptor are involved in the regulation of phospholipid transfer protein. Diabetes 2001; 50: 1851-6.
29. Diabetes Atorvastin Lipid Intervention (DALI) Study Group. The effect of aggressive versus standard lipid lowering by atorvastatin on diabetic dyslipidemia: the DALI study: a double-blind, randomized, placebo-controlled trial in patients with type 2 diabetes and diabetic dyslipidemia. Diabetes Care 2001; 24: 1335-41.
30. Dallinga-Thie GM, van Tol A, Hattori H, Rensen PC, Sijbrands EJ. Plasma phospholipid transfer protein activity is decreased in type 2 diabetes during treatment with atorvastatin: a role for apolipoprotein E? Diabetes 2006; 55: 1491-6.
31. Grundy SM, Cleeman JI, Daniels SR et al. American Heart Association; National Heart, Lung, and Blood Institute. Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement. Circulation 2005; 112: 2735-52.
32. van de Ree MA, Huisman MV, Princen HM, Meinders AE, Kluft C; DALI-Study Group. Strong decrease of high sensitivity C-reactive protein with high-dose atorvastatin in patients with type 2 diabetes mellitus. Atherosclerosis 2003; 166: 129-35.
33. Speijer H, Groener JE, van Ramshorst E, van Tol A. Different locations of cholesteryl ester transfer protein and phospholipid transfer protein activities in plasma. Atherosclerosis 1991; 90: 159-68.
34. Selvin S. Statistical Analysis of Epidemiological Data. New York: Oxford University press, 1996.
35. Fox CS, Massaro JM, Hoffmann U et al. Abdominal visceral and subcutaneous adipose tissue compartments: association with metabolic risk factors in the Framingham Heart Study. Circulation 2007; 116: 39-48.
36. Dusserre E, Moulin P, Vidal H. Differences in mRNA expression of the proteins secreted by the adipocytes in human subcutaneous and visceral adipose tissues. Biochim Biophys Acta 2000; 1500: 88-96.
37. Frayn KN, Williams CM, Arner P. Are increased plasma non-esterified fatty acid concentrations a risk marker for coronary heart disease and other chronic diseases? Clin Sci (Lond) 1996; 90: 243-53.
38. Schmidt MI, Duncan BB. Diabesity: an inflammatory metabolic condition. Clin Chem Lab Med 2003; 41: 1120-30.
39. Cao G, Beyer TP, Yang XP et al. Phospholipid transfer protein is regulated by liver X receptors in vivo. J Biol Chem 2002; 277: 39561-5.
40. Goldstein JL, Brown MS, Liang G. LXR-SREBP-1c-phospholipid transfer protein axis controls very low density lipoprotein (VLDL) particle size. J Biol Chem 2010; 285: 6801-10.
41. Dullaart RPF, Hoogenberg K, Dikkeschei BD, van Tol A. Higher plasma lipid transfer protein activities and unfavorable lipoprotein changes in cigarette-smoking men. Arterioscler Thromb 1994; 10: 1581-5.
42. Tan KC, Shiu SW, Wong Y, Tam S. Plasma phospholipid transfer protein activity and subclinical inflammation in type 2 diabetes mellitus. Atherosclerosis 2005; 178: 365-70.
43. Jänis MT, Metso J, Lankinen H et al. Apolipoprotein E activates the low-activity form of human phospholipid transfer protein. Biochem Biophys Res Commun 2005; 331: 333-40.
44. Settasatian N, Barter PJ, Rye KA. Remodeling of apolipoprotein E-containing spherical reconstituted high density lipoproteins by phospholipid transfer protein. J Lipid Res 2008; 49: 115-26.